gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.
Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4
gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.
FSHD (MIM 158900) is clinically characterized by the initial onset of facial and upper-extremity muscle weakness that is often asymmetric and progresses to involve both upper and lower extremities 1 . FSHD1 and FSHD2 are phenotypically indistinguishable, and both are associated with DNA hypomethylation and decreased repressive heterochromatin at the D4Z4 macrosatellite array, which we collectively refer to as chromatin relaxation [2] [3] [4] [5] [6] [7] [8] (Supplementary Fig. 1 ). Each D4Z4 unit encodes a copy of the DUX4 retrogene (encoding double homeobox 4) 9-13 , a transcription factor expressed in the germ line that is epigenetically repressed in somatic tissues. D4Z4 chromatin relaxation in FSHD results in inefficient epigenetic repression of DUX4 and a variegated pattern of DUX4 protein expression in a subset of skeletal muscle nuclei 14 (Supplementary Fig. 1 ). Ectopic expression of DUX4 in skeletal muscle activates the expression of stem cell and germline genes 15 , and, when overexpressed in somatic cells, DUX4 can ultimately lead to cell death 12, [16] [17] [18] [19] [20] . Chromatin relaxation in FSHD1 is associated with contraction of the array to 1-10 D4Z4 repeat units and has a dominant inheritance pattern linked to the contracted array. In FSHD2, chromatin relaxation is independent of the size of the D4Z4 array and occurs at both chromosome 4 D4Z4 arrays and at the highly homologous arrays on chromosome 10 ( Supplementary Fig. 1) 2, 7, 8, 21, 22 .
D4Z4 chromatin relaxation must occur on a specific chromosome 4 haplotype to cause FSHD1 and FSHD2. This haplotype contains a polyadenylation signal to stabilize DUX4 mRNA in skeletal muscle 13, [23] [24] [25] [26] [27] . Chromosomes 4 and 10 that lack this polyadenylation signal do not produce DUX4 protein; consequently, D4Z4 chromatin relaxation and transcriptional derepression on these nonpermissive haplotypes does not lead to disease. Because chromatin relaxation occurs at D4Z4 repeats on both chromosomes 4 and 10 in FSHD2, we sought to determine whether an inherited defect in a modifier of D4Z4 repeat-mediated epigenetic repression might cause FSHD2 when combined with an FSHD-permissive DUX4 allele.
To quantify D4Z4 chromatin relaxation, we determined the percentage of CpG methylation on the basis of measurements following cleavage with the methylation-sensitive FseI endonuclease, in an assay that averaged the percentage of D4Z4 methylation on both alleles of chromosomes 4 and 10 in a cohort of 72 controls, 93 individuals with FSHD1 and 53 individuals with FSHD2. In FSHD2affected individuals, D4Z4 methylation was at least 2 s.d. below the average levels in the general population (44% ± 10% for the general population and 11 ± 5% for individuals with FSHD2; Fig. 1a, Supplementary Fig. 2 and Supplementary Note). Using a stringent methylation threshold of <25%, we discovered that, in some kindreds identified by a proband with FSHD2, D4Z4 hypomethylation segregated in a pattern consistent with autosomal dominant inheritance that was not linked to the chromosome 4 or 10 D4Z4 array haplotype ( Fig. 1b) . In these kindreds, individuals with FSHD2 inherited both the hypomethylation trait and the FSHD-permissive chromosome 4 haplotype with the DUX4 polyadenylation signal, suggesting that two independently segregating loci cause and determine the penetrance of FSHD2.
To identify the locus controlling the D4Z4 hypomethylation trait, we performed whole-exome sequencing 28 of 14 individuals in 7 unrelated families with FSHD2: 5 with dominant segregation of the hypomethylation trait and 2 with sporadic hypomethylation and FSHD2. Detailed genetic analysis of the repeat lengths and haplotypes did not provide evidence of non-paternity in these families ( Fig. 1b) . Families were stratified according to the criterion that the D4Z4 methylation level had to be <25%, not as a result of contracted repeats on chromosomes 4 and 10 ( Supplementary Table 1 and Supplementary Note). We identified rare and potentially pathogenic mutations in the SMCHD1 gene (encoding structural maintenance of chromosomes flexible hinge domain containing 1) in all individuals with D4Z4 hypomethylation, with the exception of members of one family (Rf854; Table 1 ). These mutations were not present in public (dbSNP132 and the 1000 Genomes Project) or in house databases or in family members with normal D4Z4 methylation levels.
We confirmed the presence of these mutations by Sanger sequencing and included 12 additional unrelated families with FSHD2 from whom DNA or RNA was available. We identified heterozygous For each individual, the subject ID, FseI-detected methylation level (%) and presence (SMC, gray) or absence (CTR, white) of a SMCHD1 mutation is indicated (upper box). Also indicated in the lower two boxes are the lengths of both D4Z4 arrays on chromosomes 4 in units. Permissive alleles, typically A alleles defined on the basis of a polymorphism distal to the repeat 24 , are indicated by gray boxes. B alleles, which are nonpermissive 42 , are indicated by white boxes. Some less common subtypes of the A allele are considered to be nonpermissive 41 ; these are marked with # and colored white (Rf399 and Rf739). Note the independent segregation of D4Z4 hypomethylation and FSHD-permissive alleles. Only in those individuals in whom a permissive allele combines with D4Z4 hypomethylation (<25%) was FSHD diagnosed, whereas individuals with D4Z4 hypomethylation carrying nonpermissive alleles were unaffected by FSHD. Individuals selected for wholeexome sequencing (upper seven pedigrees) are indicated by asterisks. SMC# indicates a coding synonymous SNP identified in Rf854. A key for the symbols is included. l e t t e r s npg l e t t e r s out-of-frame deletions, heterozygous splice-site mutations and heterozygous missense mutations in SMCHD1 in 15 out of 19 families (79%; Fig. 1b , Table 1 and Supplementary Fig. 3 ). We also confirmed that the splice-site mutations altered normal SMCHD1 mRNA by excluding exons and introducing the usage of cryptic splice sites ( Supplementary Fig. 4a,b) .
Because heterozygous SMCHD1 mutations cosegregated with D4Z4 hypomethylation in families with FSHD2 or occurred de novo in individuals with sporadic hypomethylation and FSHD2 ( Fig. 1b) , we considered SMCHD1 haploinsufficiency to be a candidate disease mechanism, particularly because many of the mutations were predicted to affect production of the full-length protein. Indeed, fibroblasts from individuals with FSHD2 who had nonsynonymous or splice-site mutations in SMCHD1 expressed substantially lower amounts of SMCHD1 protein relative to control individuals ( Fig. 2a) . We found normal levels of SMCHD1 protein in the individual with FSHD2 with hypomethylated D4Z4 in family Rf854 who did not have an SMCHD1 mutation ( Fig. 2a ), suggesting that FSHD2 in this family has a genetic cause other than SMCHD1 haploinsufficiency. Finally, chromatin immunoprecipitation (ChIP) showed the presence of SMCHD1 on the D4Z4 array and detected lower levels of this association in individuals with FSHD2 who had SMCHD1 mutations ( Fig. 2b) . Taken together, these results support haploinsufficiency of SMCHD1 as a cause of D4Z4 hypomethylation in unrelated kindreds with FSHD2.
FSHD is characterized by low-level variegated expression of DUX4 in skeletal muscle. Therefore, we assessed DUX4 expression in skeletal muscle cells from control individuals after decreasing SMCHD1 levels by RNA interference (Fig. 3a,b) . We detected no DUX4 mRNA in primary myotubes from an unaffected individual with a normal-sized and methylated D4Z4 array on the FSHD-permissive DUX4 polyadenlated haplotype. In contrast, DUX4 was transcriptionally activated in these myotubes ( Fig. 3c) when SMCHD1 transcripts and protein amounts were reduced to <50% of normal. We observed a variegated pattern of DUX4 protein expression in myotubes in all samples with adequate SMCHD1 knockdown ( Fig. 3d) ; this pattern was similar to that seen in myotubes from individuals with FSHD2. Cells expressing a scrambled or ineffective short hairpin RNA (shRNA) did not express DUX4 (Fig. 3 , control and 4059).
To show that the SMCHD1 splice-site mutations identified in individuals with FSHD2 result in DUX4 expression, we manipulated SMCHD1 pre-mRNA splicing in skeletal muscle cells using antisense oligonucleotides directed against exon 29 or 36. These antisense oligonucleotides caused skipping of SMCHD1 exon 29 or 36 at rates comparable to those detected in some individuals with FSHD2 and resulted in transcription of DUX4 (Fig. 3e,f) . Thus, SMCHD1 activity is necessary for the somatic repression of DUX4, and reduction of this activity results in D4Z4 arrays that express DUX4 when an FSHD-permissive DUX4 haplotype is present, with a pattern of variegated expression similar to that observed in FSHD1 and FSHD2 myotube cultures. SMCHD1 belongs to the SMC gene superfamily that regulates chromatin repression in many different organisms, mediating the silencing of mating loci in yeast 29 , dosage compensation in Caenorhabditis elegans 30, 31 , position effect variegation in Drosophila melanogaster 32 npg l e t t e r s and RNA-directed DNA methylation in Arabidopsis thaliana 33 . SMCHD1 was first identified in a mouse mutagenesis screen for modifiers of the variegated expression of a multicopy transgene 34 . Gene targeting confirmed that Smchd1 was necessary for hypermethylation of a subset of CpG islands associated with X-chromosome inactivation, and continued association of the Smchd1 protein with the inactive X chromosome suggested its continuous requirement in maintaining X-chromosome inactivation 35, 36 . Our observations paint a similar picture of the role of SMCHD1 and the D4Z4 arrays: SMCHD1 is necessary for D4Z4 hypermethylation, SMCHD1 remains associated with the D4Z4 array in skeletal muscle cells, and its continuous expression is required to maintain array silencing. It will be interesting to examine individuals with SMCHD1 mutations for subclinical abnormalities in X-chromosome inactivation. The Smchd1 mutation was originally called the Momme D1 locus (encoding modifiers of murine metastable epialleles D1) 34 . The term metastable epiallele has been applied to genes that show variable expression because of probabilistic determinants of epigenetic repression 37 . An example of a metastable epiallele in mice is the A vy locus (encoding agouti viable yellow); coat colors of isogenic mice vary on the basis of the epigenetic state of a retrotransposon integrated near the A promoter 38 . SmcHD1 is a modifier of metastable epialleles, as Smchd1 haploinsufficiency results in higher penetrance of agouti expression 34 . In the case of FSHD, lower levels of SMCHD1 resulted in lower D4Z4 CpG methylation and variegated expression of DUX4 in myonuclei. In both FSHD1 and FSHD2, the penetrance is incomplete, and the presentation is often asymmetric. Out of the 26 individuals with hypomethylation at D4Z4 with a SMCHD1 mutation and carrying a permissive D4Z4 haplotype, 5 (19%) are asymptomatic ( Supplementary Table 2 ). This proportion of clinically unaffected carriers is notably similar to that observed in FSHD1 (ref. 39) , although a recent publication corroborates an earlier observation that non-penetrance may be much more frequent 40, 41 . Thus, both features are consistent with FSHD being a metastable epiallele-linked disease. Our demonstration that independently variable modifiers of D4Z4 chromatin relaxation (repeat size in FSHD1 and SMCHD1 activity in FSHD2) modulate the variegated expression of DUX4 suggests that DUX4 should be regarded as a metastable epiallele causing phenotypic variation in humans.
The disease mechanisms of FSHD1 and FSHD2 converge at the level of D4Z4 chromatin relaxation and the variegated expression of DUX4 (refs. 14, 15) . Both FSHD1 and FSHD2 require inheritance of two independent genetic variations: a version of the DUX4 gene with a polyadenylation signal and a second genetic variant that results in D4Z4 chromatin relaxation. For FSHD1, the genetic variant associated with chromatin relaxation involves contraction of the D4Z4 array and is therefore transmitted as a dominant trait. For FSHD2, mutations in SMCHD1, which is on chromosome 18, segregate independently from the FSHD-permissive DUX4 allele on chromosome 4 and result in a digenic inheritance pattern in affected kindreds. Considering the variable clinical severity and asymmetric disease presentation, as well as the families with FSHD2 without SMCHD1 mutations, it is likely that other modifier loci will be identified that affect D4Z4 chromatin structure. SMCHD1 mutations could also modify the penetrance of FSHD1. Finally, many other human diseases show variable penetrance that might be related to epigenetic control. Our findings establish the possibility that SMCHD1 mutations may modify the epigenetic repression of other genomic regions and the penetrance of other human diseases. npg Mutalyzer 2.0.beta-21, https://mutalyzer.nl/; NCBI, http://www. ncbi.nlm.nih.gov/; GeneCards, http://www.genecards.org/; Ensembl, http://www.ensembl.org/Homo_sapiens/Info/Index; FSHD genotyping and methylation analysis protocols, http://www.urmc.rochester.edu/ fields-center/.
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Study subjects and samples. Forty-one individuals with FSHD2 were selected on the basis of published clinical and molecular criteria 5, 7, 43, 44 and because they had D4Z4 methylation levels of <25% (Supplementary Table 1) . Assessment of the FSHD phenotype was performed by experienced neurologists. Initial testing was performed using pulsed-field gel electrophoresis and hybridization of Southern blots with P13E-11, A and B probes, and SSLP length was determined using an ABI Prism 3100 Genetic Analyzer 41, 45, 46 according to protocols at the Fields Center at the University of Rochester for FSHD Research website (see URLs). Forty of the affected individuals had D4Z4 array sizes of >10 units on both copies of chromosome 4, ruling out diagnosis with FSHD1. One affected individual had two contracted alleles on chromosome 10, possibly explaining the low D4Z4 methylation observed for this subject, and was therefore excluded from further studies. Of the 39 remaining affected families, we had sufficient family information for 13 suggesting dominant inheritance of D4Z4 hypomethylation, whereas the hypomethylation seemed to have occurred de novo in 7 affected individuals (Fig. 1b) . For exome sequencing, we selected five families with a dominant inheritance pattern and two with de novo hypomethylation in the affected individual. In total, 14 individuals from these families were analyzed by exome sequencing. All participants provided written consent, and the institutional review boards (IRBs) of participating institutes approved all studies.
D4Z4 methylation analysis.
Genomic DNA was double digested with EcoRI and BglII overnight at 37 °C, and cleaved DNA was purified using PCR extraction columns (Supplementary Note). Purified DNA digested with EcoRI and BglII was digested with FseI for 4 h, separated by size on 0.8% agarose gels, transferred to a nylon membrane (Hybond XL, Amersham) by Southern blotting and probed using the p13E-11 radiolabeled probe 22 . Probe signals were quantified using a phosphorimager and ImageQuant software. The signal from the 4,061-bp fragment was divided by the total amount of hybridizing fragments at 4,061 bp (methylated) and 3,387 bp (unmethylated) to give the percentage of methylated FseI sites within the most proximal D4Z4 unit (Supplementary Note).
Exome definition, array design and target masking.
We targeted all proteincoding regions as defined by RefSeq 36.3. Entries were filtered for (i) CDS as the feature type, (ii) transcript name starting with 'NM_' or '-' , (iii) reference as the group_label and (iv) not being on an unplaced contig (for example, 17|NT_ 113931.1). Overlapping coordinates were collapsed for a total of 31,922,798 bases over 186,040 discontiguous regions. A single custom array (Agilent, 1 million features, array-comparative genomic hybridization (aCGH) format) was designed to have probes over these coordinates as previously described, except that the maximum melting temperature (T m ) was raised to 73 °C.
The mappable exome was also determined as previously described, instead using the RefSeq 36.3 exome definition. After masking for 'unmappable' regions, 30,923,460 bases remained as the mappable target.
Targeted capture and massively parallel sequencing. Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols. DNA (5 µg) from each of the eight individuals was used for construction of a shotgun sequencing library as described previously, using paired-end adaptors for sequencing on an Illumina Genome Analyzer IIx (GAIIx). Each shotgun library was hybridized to an array for target enrichment, which was followed by washing, elution and additional amplification. Enriched libraries were then sequenced on a GAIIx to generate either single-end or paired-end reads.
Read mapping and variant analysis.
Reads were mapped and processed largely as previously described. In brief, reads were quality recalibrated using Eland and then aligned to the reference human genome (hg19) using MAQ. When reads with the same start site and orientation were filtered, paired-end reads were treated as separate single-end reads; this method is overly conservative, and, hence, the actual coverage of the exomes was higher than reported here. Sequence calls were performed using MAQ, and these calls were filtered to coordinates with ≥8× coverage and consensus quality of ≥20.
Insertions and/or deletions (indels) affecting coding sequences were identified as previously described, but we used phaster instead of cross_match and MAQ.
Specifically, unmapped reads from MAQ were aligned to the reference sequence using phaster (version 1.100122a) with the parameters -max_ins:21 -max_del:21 -gapextend_ins:-1 -gapextend_del:-1 -match_report_type:1. Reads were then filtered for those with at most two substitutions and one indel. Reads that mapped to the negative strand were reverse complemented and, together with the other filtered reads, were remapped using the same parameters to reduce ambiguity in the called indel positions. These reads were then filtered for (i) having a single indel more than 3 bp from the ends and (ii) having no other substitutions in the read. Putative indels were then called per individual if they were supported by at least two filtered reads that started from different positions. An indel reference was generated as previously described, and all the reads from each individual were mapped back to this reference using phaster with default settings and -match_report_type:1. Indel genotypes were called as previously described.
To determine whether the variants were novel, sequence calls were compared against our previously reported exome data for 1,200 individuals and the 1000 Genomes Project database and dbSNP. Annotations of variants were made on the basis of information in the NCBI and UCSC databases using an in house server (SeattleSeq Annotation). Loss-of-function variants were defined as nonsense mutations (introduction of a premature stop codon) or frameshift indels. For each variant, we also generated constraint scores, as implemented in genomic evolutionary rate profiling (GERP).
Ranking of candidate genes. Candidate genes were ranked by summation of variant scores calculated by counting the total number of nonsense and nonsynonymous variants across the FSHD2 exomes.
Mutation validation. Sanger sequencing of PCR amplicons (LGTC, Leiden, Netherlands) from genomic DNA was used to confirm the presence and identity of mutations in SMCHD1 that were initially detected via exome sequencing and to screen each mutation in the affected and unaffected family members in families with FSHD2.
Cells and culture conditions. Primary human myoblasts were obtained through the Fields Center. Biopsies were obtained after obtaining full consent with an IRB-approved protocol. Consents included the possibility of exome sequencing and sharing of samples with other investigators. Normal human myoblasts were grown on dishes coated with 0.01% calf skin collagen (Sigma-Aldrich) in F10 medium (Invitrogen) supplemented with 20% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, 4 µg/ml human basic fibroblast growth factor (bFGF) (Invitrogen) and 1 µM dexamethasone (Sigma-Aldrich) in a humidified atmosphere containing 5% CO 2 at 37 °C 13 . Transduction of human myoblasts with retroviral vectors was accomplished by seeding cells at a density of 5 × 10 4 cells/cm 2 on day −1. On day 0, the medium was changed, and cells were incubated with vector preparations and polybrene (4 µg/ml; Sigma-Aldrich). After 2-4 h, the medium was replaced with fresh medium, and cells were cultured and split at ~75% confluence to prevent differentiation. Human myoblasts transduced with pGIPZ shRNA expression vectors were selected with puromycin (0.5 µg/ml). Differentiation was induced using F10 medium supplemented with 1% horse serum and ITS supplement (insulin 0.1%, 0.000067% sodium selenite, 0.055% transferrin; Invitrogen).
Fibroblasts obtained from individuals with FSHD2 and their family members were cultured in DMEM/F-12 medium supplemented with 20% heatinactivated FBS, 1% penicillin-streptomycin, 10 mM HEPES and 1 mM sodium pyruvate (all from Invitrogen).
RNA extraction and cDNA synthesis. Total RNA was extracted using the Qiagen miRNeasy Mini isolation kit with DNase I treatment. The RNA concentration was determined on an ND-1000 spectrophotometer (Thermo-Scientific), and RNA quality was analyzed with an RNA 6000 Nanochip Labchip on an Agilent 2100 Bioanalyzer (Agilent Technologies Netherlands). cDNA was synthesized from 2 µg of total RNA using random hexamer primers (Fermentas) and the RevertAid H Minus M-MuLV First Strand kit (Fermentas Life Sciences) according to the manufacturer's instructions. After completion of cDNA synthesis, 30 µl of water was added to an end volume of 50 µl.
Semiquantitative RNA analysis and sequencing of SMCHD1 mutations. Splicing alterations were analyzed by RT-PCR using different primer sets npg covering the exons surrounding the possible splice-site mutation. Subsequently, PCR fragments generated from control samples and individuals heterozygous for SMCHD1 mutations were analyzed on 1.5-2% agarose gels. Fragments were separated by size on agarose gels, purified and analyzed by Sanger sequencing (LGTC).
Allelic expression analysis of missense mutations (wild-type versus mutant alleles) was carried out with Sanger sequencing (LGTC) by comparison of the nucleotide peak heights of the wild-type and mutant alleles.
DUX4 mRNA levels were analyzed in duplicate by RT-PCR using the SYBR Green QPCR master mix kit (Stratagene) on a MyiQ (Bio-Rad), running an initial denaturation step at 95 °C for 6 min followed by 40 cycles of 10 s at 95 °C and 30 s at 60 °C (35 cycles for the DUX4 RT-PCR samples shown in Fig. 3e,f) . All PCR products were analyzed on a 2% agarose gel. Expression levels were corrected by those of GAPDH and GUSB, constitutively expressed standards for cDNA input, and the relative steady-state RNA levels of the genes of interest were calculated by a previously described method 47 . All primers were designed using Primer3 software, and sequences are provided in Supplementary Table 3 .
ChIP assays. Chromatin was prepared from myoblast cell lines fixed with 1% formaldehyde according to a published protocol 48 . Control and FSHD2 myoblasts carried a comparable total number D4Z4 repeat units on permissive and nonpermissive chromosomes. We incubated 60 µg of chromatin with the different antibodies. Every sample was independently studied twice. Antibodies against SMCHD1 (ab31865) and histone H3 (ab1791) were purchased from Abcam. Normal rabbit serum was used to measure unspecific binding of proteins to beads. Immunopurified DNA was quantified with the D4Z4 Q-PCR primer pair 8 , and quantitative PCR measurements were performed with the CFX96 Real-Time PCR Detection System using iQ SYBRR Green Supermix. Relative enrichment values were calculated by dividing the ChIP values obtained with the antibodies to SMCHD1 or IgG by the ChIP values obtained with the antibodies to histone H3.
Antisense-mediated exon skipping. Antisense oligonucleotides for SMCHD1 exons 29 (29AON5) and 36 (36AON1) were designed on the basis of the guidelines for DMD exons ( Supplementary Table 3 ) 49 . All antisense oligonucleotides target exon-intern sequences, consist of 2′-O-methyl RNA with a full-length phosphorothioate backbone and were manufactured by Eurogentec. Human control myoblasts were seeded in 6-well plates or 6-cm dishes at a density of approximately 1 × 10 4 cells/cm 2 and were cultured for 2 d. Myotubes were obtained by growing myoblasts at 70% confluence for 4 d in differentiation medium (DMEM (with glucose, l-glutamine and pyruvate) supplemented with 2% horse serum). Cells were transfected with 250 nM concentrations of antisense oligonucleotides 4 h after the differentiation medium was added, using 2.5 µl of polyethyleneimine (MBI-Fermentas) per microgram of antisense oligonucleotide according to the manufacturer's instructions. A FAMlabeled antisense oligonucleotide targeting exon 50 of the DMD gene was used to confirm the efficiency of transfection and exon skipping. Primers flanking the targeted exons were used to study splicing of the SMCHD1 and DMD genes.
Knockdown of SMCHD1 mRNA in normal human myoblasts. SMCHD1 transcripts were targeted for degradation using lentiviral vectors expressing shRNAs from a CMV promoter linked to a puromycin selection cassette controlled by an internal ribosome entry site (IRES). Five different pGIPZ vectors (Open Biosystems) were purchased, and each was tested in normal human myoblasts for the effect on SMCHD1 transcripts by quantitative PCR, immunofluorescence signal intensity and protein blot analysis.
Antibodies, immunofluorescence and protein blotting. Immunofluorescence for human DUX4 was performed using a rabbit monoclonal antibody specific to its C terminus (Epitomics, E5-5), as previously described 15 . Immunoreactivity was detected with a mouse Alexa Fluor 594-conjugated secondary antibody to rabbit (Molecular Probes; 1:1,000 dilution).
For protein blotting, fibroblast or myoblast lysates were separated by 7.5% SDS-PAGE and transferred to PVDF membrane. SMCHD1 protein was detected using a commercially available rabbit polyclonal antibody (Sigma-Aldrich, HPA039441; 1:250 dilution), and the reference protein tubulin was detected with a commercially available mouse monoclonal antibody (Sigma, T6199; 1:2,000 dilution). Bound antibodies were detected with a horseradish peroxidase (HRP)-conjugated donkey secondary antibody to rabbit (Pierce, 31458; 1:5,000 dilution) and an IRDye 800CW-conjugated goat secondary antibody to mouse (Westburg, 926-32210; 1:5,000 dilution), respectively.
